idarubicin has been researched along with Hemorrhage in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Kanaya, M; Kondo, T | 1 |
| Al Mohareb, F; Al Qurashi, F; Al Shanqeeti, A; Al Sharif, F; Al Zahrani, H; Aljurf, M; Chaudhri, N; Iqbal, A; Nurgat, ZA; Owaidah, T; Sahovic, E; Sanz, M; Zaidi, SZ | 1 |
| Tallman, MS | 1 |
| Avvisati, G; Breccia, M; Candoni, A; Cimino, G; Di Raimondo, F; Fazi, P; Kropp, MG; Latagliata, R; Lo-Coco, F; Mandelli, F; Martinelli, G; Melillo, L; Petti, MC; Rupoli, S; Salvi, F; Sborgia, M; Tonso, A; Venditti, A; Vignetti, M; Vincelli, D | 1 |
| Amadori, S; Avvisati, G; Baccarani, M; Cantore, N; Di Bona, E; Ferrara, F; Fioritoni, G; Gallo, E; Invernizzi, R; Lazzarino, M; Liso, V; Lo-Coco, F; Mandelli, F; Mariani, G; Petti, MC; Ricciuti, F; Selleri, C; Sica, S; Vegna, ML; Veneri, D | 1 |
| Amutio, E; Bergua, JM; Brunet, S; de la Serna, J; Debén, G; Díaz-Mediavilla, J; Esteve, J; González, JD; González, M; León, A; Lowenberg, B; Milone, G; Montesinos, P; Negri, S; Parody, R; Rayón, C; Rivas, C; Sanz, MA; Tormo, M; Vellenga, E | 1 |
| Escudier, SM; Estey, EH; Kantarjian, HM | 1 |
| Feliu, E; Hernández, JA; Millá, F; Navarro, JT; Oriol, A; Pujol, M; Ribera, JM; Sancho, JM | 1 |
| Avvisati, G; Castaman, G; De Sanctis, V; Di Bona, E; Luce Vegna, M; Mandelli, F; Rodeghiero, F | 1 |
5 trial(s) available for idarubicin and Hemorrhage
| Article | Year |
|---|---|
High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Factor VIII; Female; Fibrinogen; Hemorrhage; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Pilot Projects; Remission Induction; Tretinoin; Young Adult | 2010 |
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Opportunistic Infections; Prognosis; Remission Induction; Survival Analysis; Tretinoin | 2011 |
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow
Topics: Adolescent; Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hemorrhage; Humans; Idarubicin; Infections; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Middle Aged; Remission Induction; Treatment Outcome; Vomiting | 2002 |
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Child, Preschool; Creatinine; Disease-Free Survival; Female; Hemorrhage; Humans; Idarubicin; Infections; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Risk Factors; Sex Factors; Survival Rate; Syndrome; Treatment Failure; Tretinoin | 2008 |
Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.
Topics: Adult; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cerebral Hemorrhage; Cohort Studies; Cytarabine; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Germinoma; Hemorrhage; Humans; Idarubicin; Incidence; Infarction; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Melanoma; Middle Aged; Myocardial Infarction; Neoplasms, Multiple Primary; Remission Induction; Retrospective Studies; Spleen; Thrombosis; Treatment Outcome; Tretinoin | 1996 |
4 other study(ies) available for idarubicin and Hemorrhage
| Article | Year |
|---|---|
Diffuse alveolar hemorrhage during induction therapy for acute myeloid leukemia with inv(16)(p13.1q22).
Topics: Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Diagnosis, Differential; Hemorrhage; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Lung Diseases; Male; Middle Aged; Pulmonary Alveoli; Tomography, X-Ray Computed | 2020 |
Updates on the treatment of acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cytarabine; Daunorubicin; Hemorrhage; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Tetrahydronaphthalenes; Tretinoin | 2010 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Hemorrhage; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Pancytopenia; Platelet Count; Platelet Transfusion; Retrospective Studies; Spain; Thrombocytopenia | 1998 |
Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Child; Child, Preschool; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Fibrinogen; Hemorrhage; Humans; Idarubicin; Incidence; Infant; Italy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Morbidity; Multivariate Analysis; Platelet Count; Prospective Studies; Remission Induction; Time Factors; Tretinoin | 2000 |